Belite Bio’s $36 Million IPO

Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal.Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of its…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Martina Bellini

Author: Martina Bellini

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here